Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Journal of Ocular Pharmacology and Therapeutics, Ahead of Print.

https://www.liebertpub.com/doi/abs/10.1089/jop.2021.0051?ai=s1&mi=o0fy&af=R

Source: Journal of Ocular Pharmacology and Therapeutics - September 14, 2021 Category: Opthalmology Authors: Jae Hui Kim Jong Woo Kim Chul Gu Kim Source Type: research

More News: Age-Related Macular Degeneration (AMD) | Drugs & Pharmacology | Lucentis | Opthalmology | Ranibizumab Injection